It appears that the higher the expression of PKMYT1, the shorter the survival period in luminal A, B and TNBC subtypes (Figure 3H‐J), suggesting that PKMYT1 may be a reliable biomarker for breast cancer prognosis. Here, PKMYT1 is linked to breast carcinoma.